Drug intelligence / Profile preview

TL117 + paclitaxel

Development stage: Unknown
Lead developer: Suzhou Junde Biotechnology
Modality: Small Molecules
Administration: Intravenous

Overview

**TL117 + paclitaxel** is an investigational fixed-combination therapy under clinical evaluation for recurrent or metastatic head and neck squamous cell carcinoma. TL117 is a phosphatidylinositol 3-kinase (PI3K) inhibitor, while paclitaxel is a well-established microtubule-stabilizing antineoplastic agent. The combination is designed to leverage the tumor-suppressive effects of PI3K pathway inhibition and the cytotoxic effect of microtubule stabilization to maximize anticancer activity[1]. Paclitaxel works by binding to β-tubulin and stabilizing microtubules, inhibiting their disassembly, resulting in cell cycle arrest and apoptosis[4][5].

Other names: Taxol

Targets

PI3K (Phosphoinositide-3-kinase regulatory subunit 6)Microtubule

Beyond the preview

Go deeper on TL117 + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TL117 + paclitaxel.

Explore the full profile